- Home
- HMN vs SUPN Comparison
HMN vs SUPN Comparison
Compare HMN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMN
- SUPN
- Stock Information
- Founded
- HMN 1945
- SUPN 2005
- Country
- HMN United States
- SUPN United States
- Employees
- HMN N/A
- SUPN N/A
- Industry
- HMN Property-Casualty Insurers
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- HMN Finance
- SUPN Health Care
- Exchange
- HMN Nasdaq
- SUPN Nasdaq
- Market Cap
- HMN 1.8B
- SUPN 2.0B
- IPO Year
- HMN 1991
- SUPN 2012
- Fundamental
- Price
- HMN $45.73
- SUPN $45.08
- Analyst Decision
- HMN Buy
- SUPN Buy
- Analyst Count
- HMN 5
- SUPN 2
- Target Price
- HMN $46.75
- SUPN $43.00
- AVG Volume (30 Days)
- HMN 203.2K
- SUPN 993.2K
- Earning Date
- HMN 08-06-2025
- SUPN 08-05-2025
- Dividend Yield
- HMN 3.04%
- SUPN N/A
- EPS Growth
- HMN 71.62
- SUPN 1411.53
- EPS
- HMN 3.38
- SUPN 1.14
- Revenue
- HMN $1,649,200,000.00
- SUPN $665,125,000.00
- Revenue This Year
- HMN $7.38
- SUPN $4.84
- Revenue Next Year
- HMN $6.25
- SUPN $17.69
- P/E Ratio
- HMN $13.60
- SUPN $39.44
- Revenue Growth
- HMN 6.01
- SUPN 5.55
- 52 Week Low
- HMN $33.00
- SUPN $29.16
- 52 Week High
- HMN $46.31
- SUPN $45.60
- Technical
- Relative Strength Index (RSI)
- HMN 66.07
- SUPN 75.75
- Support Level
- HMN $44.70
- SUPN $43.77
- Resistance Level
- HMN $46.31
- SUPN $45.60
- Average True Range (ATR)
- HMN 0.65
- SUPN 1.25
- MACD
- HMN 0.06
- SUPN 0.08
- Stochastic Oscillator
- HMN 79.32
- SUPN 95.64
About HMN Horace Mann Educators Corporation
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.